China National Biotec Group Company Limited Sustainability Profile
China National Biotec Group Company Limited (CNBG), headquartered in Beijing, China, is a leading player in the biopharmaceutical industry. Founded in 1998, CNBG has established itself as a pioneer in vaccine development, blood products, and diagnostic reagents, serving both domestic and international markets. With a robust presence across various regions in China and a growing footprint globally, CNBG is renowned for its innovative approach to biotechnology. The company’s core offerings include a diverse range of vaccines and biopharmaceuticals, distinguished by their high efficacy and safety profiles. As a subsidiary of China National Pharmaceutical Group Corporation (Sinopharm), CNBG has achieved significant milestones, including the development of several key vaccines that have contributed to public health initiatives. Its commitment to research and development positions CNBG as a formidable entity in the global biopharmaceutical landscape.
DitchCarbon Score
How does China National Biotec Group Company Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China National Biotec Group Company Limited's score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China National Biotec Group Company Limited, headquartered in China (CN), currently does not report specific carbon emissions data for the most recent year. The company is a current subsidiary of China National Pharmaceutical Group Corporation, which may influence its climate-related initiatives and performance metrics. As of now, there are no documented reduction targets or climate pledges from China National Biotec Group. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. Given the context of the pharmaceutical industry, it is essential for companies like China National Biotec Group to establish clear carbon reduction strategies and align with global climate standards. This includes potentially adopting Science-Based Targets Initiative (SBTi) guidelines and participating in climate disclosure frameworks such as CDP. In summary, while China National Biotec Group has not disclosed specific emissions figures or reduction targets, its affiliation with China National Pharmaceutical Group Corporation may provide a pathway for future climate commitments and performance improvements.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,400 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is China National Biotec Group Company Limited's Industry?
How Carbon Intensive is China National Biotec Group Company Limited's Location?
China National Biotec Group Company Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
China National Biotec Group Company Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
